Lupin and Tenpoint Therapeutics Form Strategic Alliance for YUVEZZI™ Launch

Strategic Collaboration to Market YUVEZZI™

On August 20, 2026, Lupin Limited, a prominent global pharmaceutical company, disclosed its collaboration with Tenpoint Therapeutics to market YUVEZZI™, an innovative daily eye drop solution aimed at treating presbyopia in multiple European territories. This strategic partnership is expected to significantly broaden the availability of this unique dual-action treatment for presbyopia, exemplifying a commitment to improving patient access to specialized therapies in the burgeoning eye care segment.

Headquartered in Mumbai, India, Lupin Limited has taken a significant step by leveraging its subsidiary, VISUfarma B.V., which will assume exclusive rights for regulatory operations, marketing, and distribution of YUVEZZI™ in key markets such as the European Union, the United Kingdom, Switzerland, Norway, and Iceland. This exclusive licensing agreement is in line with Lupin's strategy to expand its footprint in the ophthalmic space through innovative products that meet unmet patient needs.

Investment and Regulatory Pursuits

As part of the agreement, VISUfarma will explore a strategic investment in Tenpoint Therapeutics. Both companies anticipate the potential for milestone payments tied to regulatory approvals, along with tiered royalties based on net sales. This collaborative effort is designed to optimize commercial efforts for YUVEZZI™, further extending the reach of this crucial treatment.

Vinita Gupta, CEO of Lupin, expressed enthusiasm about the partnership, highlighting how it aligns with Lupin's specialized care strategy. She remarked, "We are thrilled to partner with Tenpoint Therapeutics to offer a new ophthalmic therapy that enhances our specialized care initiatives. With YUVEZZI™, we seek to broaden access to differentiated therapies, improve patient outcomes, and fortify our leadership in eye care within licensed territories."

Henric Bjarke, CEO of Tenpoint, echoed this sentiment, stating, "This exciting alliance signifies a pivotal move for Tenpoint as we work towards making YUVEZZI™ accessible to millions suffering from presbyopia worldwide. Lupin's strong commercial presence in major European markets, coupled with VISUfarma's established expertise in ophthalmology, makes this collaboration a strategic fit. We look forward to working closely together to launch YUVEZZI™ in Europe."

YUVEZZI™: A Revolutionary Treatment

YUVEZZI™, which integrates carbachol and brimonidine into a dual-action formula, is the first of its kind daily eye drop therapy that addresses presbyopia. This condition, which typically manifests around the age of 45, leads to a gradual decline in near vision sharpness—a growing concern for millions globally. By using this innovative solution, patients can enjoy improved near vision, as carbachol facilitates pupil contraction while brimonidine controls excessive pupil dilation.

Currently, Tenpoint is actively pursuing the commercialization of YUVEZZI™ in the United States, where it has recently received FDA approval. This strategic partnership with Lupin further solidifies YUVEZZI™'s market potential, as Tenpoint is also in the process of submitting a marketing authorization application in the UK via the MHRA's International Recognition Procedure. Plans for regulatory submissions in other crucial global regions are also underway, aiming to establish a widespread availability of YUVEZZI™ internationally.

About Lupin Limited

Founded in 1968, Lupin Limited has emerged as a global leader in the pharmaceutical industry, with a diverse portfolio encompassing generic medicines, specialized products, and biosimilars. With a presence in over 100 markets, Lupin places strong emphasis on areas such as cardiovascular health, diabetes, women's healthcare, and respiratory & gastrointestinal medicines. The company’s commitment to sustainability and innovation drives its continued success in expanding health ecosystems through digital health initiatives and patient support programs.

To learn more, visit Lupin's official website.

About Tenpoint Therapeutics

Tenpoint Therapeutics is dedicated to innovating the treatment landscape for presbyopia, a condition affecting nearly 128 million individuals in the U.S. alone, and approximately 2 billion worldwide. Focusing on collaboration with vision health professionals, Tenpoint aims to revolutionize eye care with its flagship product, YUVEZZI™. For further details, explore Tenpoint Therapeutics.

This strategic alliance between Lupin and Tenpoint not only signifies a commitment to enhancing patient care through innovative treatments but also stands as a prime example of synergistic partnerships driving advancements in the healthcare sector.